[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4CpT5bU-oeulvDuv0jE7oNZzATdVKvQKn7K29bAdJcs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"Sheffield Teaching Hospitals NHS Foundation Trust",[4],209,false,21,6,22354,3,172,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Obesity",8,{"name":18,"count":19},"Osteoporosis",7,{"name":21,"count":22},"Coronary Artery Disease",5,{"name":24,"count":25},"Cystic Fibrosis",4,{"name":27,"count":25},"Multiple Sclerosis",{"name":29,"count":25},"Pulmonary Hypertension",{"name":31,"count":11},"Epilepsy",{"name":33,"count":11},"Stroke",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05825417","Pulmonary Hypertension: Intensification and Personalisation of Combination Rx","2026-01","Selexipag",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06905405","The Use of Advanced Imaging in HFpEF","2027-07-31","SGLT-2 inhibitor",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,78,96,117,155,185,214,250,275,301,326,344,372,390,408,434,452,470,488,515,541,565,595,613,637,660,684,708,732,757,775,799,825,853,871,889,915,941,965,990,1016,1034,1059,1083,1106,1131,1155],{"intervention":39,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":65,"NA":76},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":58},[],{"trials":66,"activeCount":54,"soonestReadout":38},[67],{"nctId":36,"briefTitle":37,"status":68,"phases":69,"primaryCompletion":38,"completion":38,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[50],"2023-06-14",40,[73],"Pulmonary Arterial Hypertension",[39,75],"Riociguat",{"trials":77,"activeCount":58},[],{"intervention":75,"totalTrials":54,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":88,"NA":94},{"trials":81,"activeCount":58},[],{"trials":83,"activeCount":58},[],{"trials":85,"activeCount":58},[],{"trials":87,"activeCount":58},[],{"trials":89,"activeCount":54,"soonestReadout":38},[90],{"nctId":36,"briefTitle":37,"status":68,"phases":91,"primaryCompletion":38,"completion":38,"start":70,"enrollment":71,"conditions":92,"interventions":93},[50],[73],[39,75],{"trials":95,"activeCount":58},[],{"intervention":44,"totalTrials":54,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":99,"activeCount":58},[],{"trials":101,"activeCount":58},[],{"trials":103,"activeCount":58},[],{"trials":105,"activeCount":58},[],{"trials":107,"activeCount":58},[],{"trials":109,"activeCount":54,"soonestReadout":43},[110],{"nctId":41,"briefTitle":42,"status":68,"phases":111,"primaryCompletion":43,"completion":112,"start":113,"enrollment":71,"conditions":114,"interventions":116},[],"2027-09-30","2025-08-05",[115],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[44],{"intervention":118,"totalTrials":119,"cells":120},"Aspirin",2,{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":153},{"trials":122,"activeCount":58},[],{"trials":124,"activeCount":58},[],{"trials":126,"activeCount":58},[],{"trials":128,"activeCount":58},[],{"trials":130,"activeCount":58},[131,144],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT03869268","The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","COMPLETED",[50],"2021-12-10","2023-02-09","2019-04-24",72,[141],"Acute Coronary Syndrome",[118,143],"Ticagrelor",{"nctId":145,"briefTitle":146,"status":134,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"NCT02741817","WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)",[50],"2017-04-07","2016-06-26",20,[141],[118],{"trials":154,"activeCount":58},[],{"intervention":143,"totalTrials":119,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":183},{"trials":158,"activeCount":58},[],{"trials":160,"activeCount":58},[],{"trials":162,"activeCount":58},[],{"trials":164,"activeCount":58},[],{"trials":166,"activeCount":58},[167,171],{"nctId":132,"briefTitle":133,"status":134,"phases":168,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":169,"interventions":170},[50],[141],[118,143],{"nctId":172,"briefTitle":173,"status":134,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT01846559","The Antiplatelet and Immune Response Trial",[50],"2014-01","2013-04",30,[179],"Healthy",[181,182,143],"Endotoxin","Clopidogrel",{"trials":184,"activeCount":58},[],{"intervention":182,"totalTrials":119,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":212},{"trials":188,"activeCount":58},[],{"trials":190,"activeCount":58},[],{"trials":192,"activeCount":58},[],{"trials":194,"activeCount":58},[],{"trials":196,"activeCount":58},[197,201],{"nctId":172,"briefTitle":173,"status":134,"phases":198,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":199,"interventions":200},[50],[179],[181,182,143],{"nctId":202,"briefTitle":203,"status":134,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT02327624","STEEL Percutaneous Coronary Intervention",[50],"2018-05-31","2015-06",180,[21],[182,210,211],"Ticagrelor 60","Ticagrelor 90",{"trials":213,"activeCount":58},[],{"intervention":215,"totalTrials":119,"cells":216},"Enoxaparin",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":248},{"trials":218,"activeCount":58},[],{"trials":220,"activeCount":58},[],{"trials":222,"activeCount":58},[],{"trials":224,"activeCount":58},[],{"trials":226,"activeCount":58},[227,237],{"nctId":228,"briefTitle":229,"status":134,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT03568838","Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention",[50],"2020-05-01","2018-06-28",100,[235],"Myocardial Infarction",[215],{"nctId":238,"briefTitle":239,"status":134,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT03146858","Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study",[50],"2017-12-30","2018-03-30","2017-08-25",22,[246],"Primary Percutaneous Coronary Intervention",[215],{"trials":249,"activeCount":58},[],{"intervention":251,"totalTrials":54,"cells":252},"Nebido",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":273},{"trials":254,"activeCount":58},[],{"trials":256,"activeCount":58},[],{"trials":258,"activeCount":58},[],{"trials":260,"activeCount":58},[],{"trials":262,"activeCount":58},[263],{"nctId":264,"briefTitle":265,"status":134,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT00131183","Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina",[50],"2008-05","2005-09",15,[271],"Angina Pectoris",[251],{"trials":274,"activeCount":58},[],{"intervention":276,"totalTrials":54,"cells":277},"Creon",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":299},{"trials":279,"activeCount":58},[],{"trials":281,"activeCount":58},[],{"trials":283,"activeCount":58},[],{"trials":285,"activeCount":58},[],{"trials":287,"activeCount":58},[288],{"nctId":289,"briefTitle":290,"status":291,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":119,"conditions":295,"interventions":298},"NCT01865695","Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase","TERMINATED",[50],"2014-08","2013-05",[296,297],"Patients With Coeliac Disease and Chronic Diarrhoea (>3 Loose\u002F Liquid Motions a Day for More Than 4 Weeks)","Patients With Pancreatic Exocrine Insufficiency",[276],{"trials":300,"activeCount":58},[],{"intervention":302,"totalTrials":54,"cells":303},"Decapeptyl SR 11.25mg",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":324},{"trials":305,"activeCount":58},[],{"trials":307,"activeCount":58},[],{"trials":309,"activeCount":58},[],{"trials":311,"activeCount":58},[],{"trials":313,"activeCount":58},[314],{"nctId":315,"briefTitle":316,"status":134,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT00735852","Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women",[50],"2016-05","2008-12",31,[322],"Endometriosis",[302],{"trials":325,"activeCount":58},[],{"intervention":181,"totalTrials":54,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":342},{"trials":329,"activeCount":58},[],{"trials":331,"activeCount":58},[],{"trials":333,"activeCount":58},[],{"trials":335,"activeCount":58},[],{"trials":337,"activeCount":58},[338],{"nctId":172,"briefTitle":173,"status":134,"phases":339,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":340,"interventions":341},[50],[179],[181,182,143],{"trials":343,"activeCount":58},[],{"intervention":345,"totalTrials":54,"cells":346},"Aspirin 75mg",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":370},{"trials":348,"activeCount":58},[],{"trials":350,"activeCount":58},[],{"trials":352,"activeCount":58},[],{"trials":354,"activeCount":58},[],{"trials":356,"activeCount":58},[357],{"nctId":358,"briefTitle":359,"status":134,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT04990791","WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?",[50],"2023-08-31","2023-12-01","2021-08-26",48,[366],"Coronary Syndrome",[345,368,369],"Aspirin 20mg","Rivaroxaban 2.5 mg",{"trials":371,"activeCount":58},[],{"intervention":368,"totalTrials":54,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":388},{"trials":375,"activeCount":58},[],{"trials":377,"activeCount":58},[],{"trials":379,"activeCount":58},[],{"trials":381,"activeCount":58},[],{"trials":383,"activeCount":58},[384],{"nctId":358,"briefTitle":359,"status":134,"phases":385,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":386,"interventions":387},[50],[366],[345,368,369],{"trials":389,"activeCount":58},[],{"intervention":369,"totalTrials":54,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":406},{"trials":393,"activeCount":58},[],{"trials":395,"activeCount":58},[],{"trials":397,"activeCount":58},[],{"trials":399,"activeCount":58},[],{"trials":401,"activeCount":58},[402],{"nctId":358,"briefTitle":359,"status":134,"phases":403,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":404,"interventions":405},[50],[366],[345,368,369],{"trials":407,"activeCount":58},[],{"intervention":409,"totalTrials":54,"cells":410},"morphine",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":432},{"trials":412,"activeCount":58},[],{"trials":414,"activeCount":58},[],{"trials":416,"activeCount":58},[],{"trials":418,"activeCount":58},[],{"trials":420,"activeCount":58},[421],{"nctId":422,"briefTitle":423,"status":134,"phases":424,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT01536964","The Effect of Morphine on Prasugrel Absorption in STEMI Patients",[50],"2013-03","2012-04",12,[429],"Cardiovascular Disease",[409,431],"saline",{"trials":433,"activeCount":58},[],{"intervention":431,"totalTrials":54,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":450},{"trials":437,"activeCount":58},[],{"trials":439,"activeCount":58},[],{"trials":441,"activeCount":58},[],{"trials":443,"activeCount":58},[],{"trials":445,"activeCount":58},[446],{"nctId":422,"briefTitle":423,"status":134,"phases":447,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":448,"interventions":449},[50],[429],[409,431],{"trials":451,"activeCount":58},[],{"intervention":210,"totalTrials":54,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":468},{"trials":455,"activeCount":58},[],{"trials":457,"activeCount":58},[],{"trials":459,"activeCount":58},[],{"trials":461,"activeCount":58},[],{"trials":463,"activeCount":58},[464],{"nctId":202,"briefTitle":203,"status":134,"phases":465,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":466,"interventions":467},[50],[21],[182,210,211],{"trials":469,"activeCount":58},[],{"intervention":211,"totalTrials":54,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":486},{"trials":473,"activeCount":58},[],{"trials":475,"activeCount":58},[],{"trials":477,"activeCount":58},[],{"trials":479,"activeCount":58},[],{"trials":481,"activeCount":58},[482],{"nctId":202,"briefTitle":203,"status":134,"phases":483,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":484,"interventions":485},[50],[21],[182,210,211],{"trials":487,"activeCount":58},[],{"intervention":489,"totalTrials":54,"cells":490},"Klean Prep",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":513},{"trials":492,"activeCount":58},[],{"trials":494,"activeCount":58},[],{"trials":496,"activeCount":58},[],{"trials":498,"activeCount":58},[],{"trials":500,"activeCount":58},[501],{"nctId":502,"briefTitle":503,"status":134,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":512},"NCT03351972","Differences in Preparation for Small Bowel Capsule Endoscopy",[50],"2025-03-31","2017-11-23",230,[509,510,511],"Capsule Endoscopy","Inflammatory Bowel Diseases","Celiac Disease",[489],{"trials":514,"activeCount":58},[],{"intervention":516,"totalTrials":54,"cells":517},"Entonox",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":539},{"trials":519,"activeCount":58},[],{"trials":521,"activeCount":58},[],{"trials":523,"activeCount":58},[],{"trials":525,"activeCount":58},[],{"trials":527,"activeCount":58},[528],{"nctId":529,"briefTitle":530,"status":134,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":233,"conditions":534,"interventions":538},"NCT01865721","Optimizing the Use of Entonox® During Screening Colonoscopy",[50],"2014-04","2013-01",[535,536,516,537],"Bowel Cancer Screening","Analgesia","Colonoscopy",[516],{"trials":540,"activeCount":58},[],{"intervention":542,"totalTrials":54,"cells":543},"Teriparatide",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":563},{"trials":545,"activeCount":58},[],{"trials":547,"activeCount":58},[],{"trials":549,"activeCount":58},[],{"trials":551,"activeCount":58},[],{"trials":553,"activeCount":58},[554],{"nctId":555,"briefTitle":556,"status":134,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT01293292","Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action",[50],"2015-08","2011-01",19,[18],[542],{"trials":564,"activeCount":58},[],{"intervention":566,"totalTrials":54,"cells":567},"Engerix B",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":591,"NA":593},{"trials":569,"activeCount":58},[],{"trials":571,"activeCount":58},[],{"trials":573,"activeCount":58},[],{"trials":575,"activeCount":58},[576],{"nctId":577,"briefTitle":578,"status":134,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":589},"NCT02434848","A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses",[48,49],"2022-06-10","2015-07-23",13,[584,585,586,587,588],"HIV","Communicable Diseases","Hepatitis B","HBV","Infectious Diseases",[566,590],"Fendrix",{"trials":592,"activeCount":58},[],{"trials":594,"activeCount":58},[],{"intervention":590,"totalTrials":54,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":609,"NA":611},{"trials":598,"activeCount":58},[],{"trials":600,"activeCount":58},[],{"trials":602,"activeCount":58},[],{"trials":604,"activeCount":58},[605],{"nctId":577,"briefTitle":578,"status":134,"phases":606,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":607,"interventions":608},[48,49],[584,585,586,587,588],[566,590],{"trials":610,"activeCount":58},[],{"trials":612,"activeCount":58},[],{"intervention":614,"totalTrials":54,"cells":615},"Mepolizumab 100 MG",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":633,"NA":635},{"trials":617,"activeCount":58},[],{"trials":619,"activeCount":58},[],{"trials":621,"activeCount":58},[],{"trials":623,"activeCount":58},[624],{"nctId":625,"briefTitle":626,"status":134,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":320,"conditions":630,"interventions":632},"NCT05138250","A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD",[49],"2025-05-08","2022-05-08",[631],"COPD",[614],{"trials":634,"activeCount":58},[],{"trials":636,"activeCount":58},[],{"intervention":638,"totalTrials":54,"cells":639},"Spironolactone",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":641,"activeCount":58},[],{"trials":643,"activeCount":58},[],{"trials":645,"activeCount":58},[646],{"nctId":647,"briefTitle":648,"status":291,"phases":649,"completion":319,"start":650,"enrollment":71,"conditions":651,"interventions":653},"NCT00430794","The Efficacy of Spironolactone in Patients With Resistant Hypertension",[48],"2007-03",[652],"Hypertension",[638],{"trials":655,"activeCount":58},[],{"trials":657,"activeCount":58},[],{"trials":659,"activeCount":58},[],{"intervention":661,"totalTrials":54,"cells":662},"Saracatinib",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":664,"activeCount":58},[],{"trials":666,"activeCount":58},[],{"trials":668,"activeCount":58},[669],{"nctId":670,"briefTitle":671,"status":134,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":427,"conditions":675,"interventions":677},"NCT02085603","SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain",[48],"2018-01-21","2014-03",[676],"Cancer",[661],{"trials":679,"activeCount":58},[],{"trials":681,"activeCount":58},[],{"trials":683,"activeCount":58},[],{"intervention":685,"totalTrials":54,"cells":686},"Live attenuated Vaccine- Fluenz Tretra",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":688,"activeCount":58},[],{"trials":690,"activeCount":58},[],{"trials":692,"activeCount":58},[693],{"nctId":694,"briefTitle":695,"status":134,"phases":696,"primaryCompletion":206,"completion":206,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT02266992","Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study",[48],"2014-09",28,[700],"Acquired Immune Deficiency Syndrome Virus",[685],{"trials":703,"activeCount":58},[],{"trials":705,"activeCount":58},[],{"trials":707,"activeCount":58},[],{"intervention":709,"totalTrials":54,"cells":710},"Ursonorm",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":712,"activeCount":58},[],{"trials":714,"activeCount":58},[],{"trials":716,"activeCount":58},[717],{"nctId":718,"briefTitle":719,"status":134,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":320,"conditions":723,"interventions":725},"NCT03840005","Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The \"UP\" Study",[48],"2021-05-13","2018-12-18",[724],"Parkinson's Disease",[709],{"trials":727,"activeCount":58},[],{"trials":729,"activeCount":58},[],{"trials":731,"activeCount":58},[],{"intervention":733,"totalTrials":54,"cells":734},"5-FU, Epirubicin, Cyclophosphamide, Docetaxel",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":736,"activeCount":58},[],{"trials":738,"activeCount":58},[],{"trials":740,"activeCount":58},[741],{"nctId":742,"briefTitle":743,"status":134,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":71,"conditions":747,"interventions":749},"NCT00525759","Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer",[48],"2010-01","2007-07",[748],"Breast Cancer",[733,750],"5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid",{"trials":752,"activeCount":58},[],{"trials":754,"activeCount":58},[],{"trials":756,"activeCount":58},[],{"intervention":750,"totalTrials":54,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":760,"activeCount":58},[],{"trials":762,"activeCount":58},[],{"trials":764,"activeCount":58},[765],{"nctId":742,"briefTitle":743,"status":134,"phases":766,"primaryCompletion":745,"completion":745,"start":746,"enrollment":71,"conditions":767,"interventions":768},[48],[748],[733,750],{"trials":770,"activeCount":58},[],{"trials":772,"activeCount":58},[],{"trials":774,"activeCount":58},[],{"intervention":776,"totalTrials":54,"cells":777},"Pasireotide",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":779,"activeCount":58},[],{"trials":781,"activeCount":58},[],{"trials":783,"activeCount":58},[784],{"nctId":785,"briefTitle":786,"status":291,"phases":787,"primaryCompletion":558,"completion":788,"start":789,"enrollment":16,"conditions":790,"interventions":792},"NCT01617733","Pasireotide Therapy in Patients With Nelson's Syndrome",[48],"2015-12","2011-03",[791],"Nelson Syndrome",[776],{"trials":794,"activeCount":58},[],{"trials":796,"activeCount":58},[],{"trials":798,"activeCount":58},[],{"intervention":800,"totalTrials":54,"cells":801},"Axitinib",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":803,"activeCount":58},[],{"trials":805,"activeCount":58},[],{"trials":807,"activeCount":58},[808],{"nctId":809,"briefTitle":810,"status":134,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":818},"NCT01140737","A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas",[48],"2016-06-11","2019-01-08","2010-08-31",145,[817],"Soft Tissue Sarcoma",[800],{"trials":820,"activeCount":58},[],{"trials":822,"activeCount":58},[],{"trials":824,"activeCount":58},[],{"intervention":826,"totalTrials":54,"cells":827},"Ibandronate",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":829,"activeCount":58},[],{"trials":831,"activeCount":58},[],{"trials":833,"activeCount":58},[834],{"nctId":835,"briefTitle":836,"status":134,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT00666627","Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects",[48],"2012-09","2014-12","2007-04",410,[843],"Post-menopausal Osteoporosis",[826,845,846],"Risedronate","Alendronate",{"trials":848,"activeCount":58},[],{"trials":850,"activeCount":58},[],{"trials":852,"activeCount":58},[],{"intervention":845,"totalTrials":54,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":856,"activeCount":58},[],{"trials":858,"activeCount":58},[],{"trials":860,"activeCount":58},[861],{"nctId":835,"briefTitle":836,"status":134,"phases":862,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":863,"interventions":864},[48],[843],[826,845,846],{"trials":866,"activeCount":58},[],{"trials":868,"activeCount":58},[],{"trials":870,"activeCount":58},[],{"intervention":846,"totalTrials":54,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":874,"activeCount":58},[],{"trials":876,"activeCount":58},[],{"trials":878,"activeCount":58},[879],{"nctId":835,"briefTitle":836,"status":134,"phases":880,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":881,"interventions":882},[48],[843],[826,845,846],{"trials":884,"activeCount":58},[],{"trials":886,"activeCount":58},[],{"trials":888,"activeCount":58},[],{"intervention":890,"totalTrials":54,"cells":891},"Denosumab",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":893,"activeCount":58},[],{"trials":895,"activeCount":58},[],{"trials":897,"activeCount":58},[898],{"nctId":899,"briefTitle":900,"status":134,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":908},"NCT01358669","Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty",[48],"2019-01-02","2021-12-31","2011-12-14",24,[907],"Revision Surgery of Total Hip Arthroplasty",[890],{"trials":910,"activeCount":58},[],{"trials":912,"activeCount":58},[],{"trials":914,"activeCount":58},[],{"intervention":916,"totalTrials":54,"cells":917},"Cannabis based medicine extract",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":919,"activeCount":58},[],{"trials":921,"activeCount":58},[],{"trials":923,"activeCount":58},[924],{"nctId":925,"briefTitle":926,"status":134,"phases":927,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":934},"NCT00238550","Study of CBME in the Relief of Painful Diabetic Neuropathy",[48],"2006-03","2003-10",36,[932,933],"Diabetic Neuropathy","Painful",[916],{"trials":936,"activeCount":58},[],{"trials":938,"activeCount":58},[],{"trials":940,"activeCount":58},[],{"intervention":942,"totalTrials":54,"cells":943},"Folic acid with riboflavin",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":945,"activeCount":58},[],{"trials":947,"activeCount":58},[],{"trials":949,"activeCount":58},[950],{"nctId":951,"briefTitle":952,"status":291,"phases":953,"completion":954,"start":955,"enrollment":207,"conditions":956,"interventions":958},"NCT00220532","Folate and Protection Against Cervical Cancer",[47,48],"2007-05","2005-07",[957],"Cervical Cancer",[942],{"trials":960,"activeCount":58},[],{"trials":962,"activeCount":58},[],{"trials":964,"activeCount":58},[],{"intervention":966,"totalTrials":54,"cells":967},"Selumetinib",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":969,"activeCount":58},[],{"trials":971,"activeCount":58},[],{"trials":973,"activeCount":58},[974],{"nctId":975,"briefTitle":976,"status":291,"phases":977,"primaryCompletion":978,"completion":979,"start":980,"enrollment":560,"conditions":981,"interventions":983},"NCT01752569","A Study of Selumetinib in Patients With Kaposi's Sarcoma",[47,48],"2015-09-30","2017-12-20","2012-06-15",[982],"AIDS-related Kaposi's Sarcoma",[966],{"trials":985,"activeCount":58},[],{"trials":987,"activeCount":58},[],{"trials":989,"activeCount":58},[],{"intervention":991,"totalTrials":54,"cells":992},"crisaborole (2%) ointment",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":994,"activeCount":58},[],{"trials":996,"activeCount":58},[],{"trials":998,"activeCount":58},[999],{"nctId":1000,"briefTitle":1001,"status":134,"phases":1002,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1008},"NCT04194814","Skin bioMARkers for Atopic Eczema Therapy Evaluation",[48],"2021-09-30","2020-11-20",37,[1007],"Atopic Eczema\u002FDermatitis (Non-Specific)",[991,1009],"betamethasone valerate 0.1% cream",{"trials":1011,"activeCount":58},[],{"trials":1013,"activeCount":58},[],{"trials":1015,"activeCount":58},[],{"intervention":1009,"totalTrials":54,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":58},[],{"trials":1021,"activeCount":58},[],{"trials":1023,"activeCount":58},[1024],{"nctId":1000,"briefTitle":1001,"status":134,"phases":1025,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":1026,"interventions":1027},[48],[1007],[991,1009],{"trials":1029,"activeCount":58},[],{"trials":1031,"activeCount":58},[],{"trials":1033,"activeCount":58},[],{"intervention":1035,"totalTrials":54,"cells":1036},"testosterone undecanoate",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1038,"activeCount":58},[],{"trials":1040,"activeCount":58},[],{"trials":1042,"activeCount":58},[1043],{"nctId":1044,"briefTitle":1045,"status":134,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":11,"conditions":1049,"interventions":1052},"NCT01919294","Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)",[48],"2017-01-30","2013-07",[1050,1051],"Nonalcoholic Steatohepatitis","Hypogonadism",[1035],{"trials":1054,"activeCount":58},[],{"trials":1056,"activeCount":58},[],{"trials":1058,"activeCount":58},[],{"intervention":1060,"totalTrials":54,"cells":1061},"Mifepristone",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1063,"activeCount":58},[],{"trials":1065,"activeCount":58},[],{"trials":1067,"activeCount":58},[1068],{"nctId":1069,"briefTitle":1070,"status":134,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":9,"conditions":1074,"interventions":1076},"NCT00721201","Glucocorticoid Receptor Antagonism in Subclinical Cushings",[47,48],"2010-03","2008-11",[1075],"Subclinical Cushing's",[1060],{"trials":1078,"activeCount":58},[],{"trials":1080,"activeCount":58},[],{"trials":1082,"activeCount":58},[],{"intervention":1084,"totalTrials":54,"cells":1085},"Clopidogrel and Rifampicin",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1087,"activeCount":58},[],{"trials":1089,"activeCount":58},[1090],{"nctId":1091,"briefTitle":1092,"status":134,"phases":1093,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":427,"conditions":1096,"interventions":1097},"NCT00696566","Healthy Volunteer Study of Clopidogrel and Rifampicin",[47],"2008-03","2007-11",[21],[1084],{"trials":1099,"activeCount":58},[],{"trials":1101,"activeCount":58},[],{"trials":1103,"activeCount":58},[],{"trials":1105,"activeCount":58},[],{"intervention":1107,"totalTrials":54,"cells":1108},"local anaesthetic",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1110,"activeCount":58},[],{"trials":1112,"activeCount":58},[],{"trials":1114,"activeCount":58},[],{"trials":1116,"activeCount":58},[],{"trials":1118,"activeCount":58},[],{"trials":1120,"activeCount":58},[1121],{"nctId":1122,"briefTitle":1123,"status":134,"phases":1124,"primaryCompletion":206,"completion":206,"start":1125,"enrollment":269,"conditions":1126,"interventions":1130},"NCT03137615","The Cardiovascular Changes Associated With Septal Local Anaesthesia",[],"2014-11",[1127,1128,1129],"Hypothalamic Neoplasms","Pituitary Diseases","Anesthesia, Local",[1107],{"intervention":1132,"totalTrials":54,"cells":1133},"lactamica",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1135,"activeCount":58},[],{"trials":1137,"activeCount":58},[],{"trials":1139,"activeCount":58},[],{"trials":1141,"activeCount":58},[],{"trials":1143,"activeCount":58},[],{"trials":1145,"activeCount":58},[1146],{"nctId":1147,"briefTitle":1148,"status":134,"phases":1149,"primaryCompletion":1150,"start":1048,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT02249598","Competitive Carriage of Neisseria Spp(Lactamica 2)",[51],"2013-11",300,[1153],"Neisseria Lactamica",[1132],{"intervention":1156,"totalTrials":54,"cells":1157},"Orlistat Vs Metformin",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1159,"activeCount":58},[],{"trials":1161,"activeCount":58},[],{"trials":1163,"activeCount":58},[],{"trials":1165,"activeCount":58},[],{"trials":1167,"activeCount":58},[],{"trials":1169,"activeCount":58},[1170],{"nctId":1171,"briefTitle":1172,"status":134,"phases":1173,"primaryCompletion":1174,"completion":1174,"start":1175,"enrollment":930,"conditions":1176,"interventions":1178},"NCT00292799","An RCT of Metformin Vs Orlistat in Obese Anovulatory Women",[51],"2008-02","2006-02",[1177,15],"Anovulation",[1156]]